Alaunos Therapeutics
TCRT
133 hedge funds and large institutions have $171M invested in Alaunos Therapeutics in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 15 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
0% more funds holding
Funds holding: 133 → 133 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
0.01% less ownership
Funds ownership: 0.27% → 0.26% (-0.01%)
25% less capital invested
Capital invested by funds: $228M → $171M (-$56.5M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
63% less call options, than puts
Call options by funds: $1.39M | Put options by funds: $3.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.03M |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$791K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$735K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$698K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$673K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$7.05M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.4M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.14M |
| 5 |
Renaissance Technologies
New York
|
-$942K |
TCRT Hedge Fund Activity: Q2 2018 in Review
133 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2018, worth a combined $171M — down 25% from $228M a quarter earlier.
Fund positioning in TCRT was balanced in Q2 2018: 15 funds opened new positions, 15 closed out, 37 added to existing stakes and 36 trimmed.
The largest buyer was BlackRock, adding an estimated $3.03M. The largest seller was State Street, cutting an estimated $7.05M.
- 133 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $171M of Alaunos Therapeutics stock for Q2 2018, down 25% quarter-over-quarter.
- 15 funds opened new Alaunos Therapeutics positions in Q2 2018 and 15 closed out, a net change of 0 holders.
- The largest Alaunos Therapeutics buyer in Q2 2018 was BlackRock, an estimated $3.03M added.
- The largest Alaunos Therapeutics seller in Q2 2018 was State Street, an estimated $7.05M sold.
Based on aggregated 13F filings for Q2 2018.